Literature DB >> 17656254

Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas.

Ahmed Idbaih1, Blandine Boisselier, Marc Sanson, Emmanuelle Crinière, Stéphane Liva, Yannick Marie, Catherine Carpentier, Sophie Paris, Florence Laigle-Donadey, Karima Mokhtari, Michèle Kujas, Khê Hoang-Xuan, Olivier Delattre, Jean-Yves Delattre.   

Abstract

About 5% of gliomas occur in a familial context, which suggests a genetic origin, but the predisposing molecular factors remain unknown in most cases. A series of nine familial gliomas were characterized with 1-megabase resolution BAC array-based comparative genomic hybridization (aCGH) together with germline sequence analysis of TP53. This series was compared with a literature series of familial gliomas and a personal series of sporadic gliomas, analyzed by chromosome CGH and aCGH, respectively. No significant difference was noted between the three populations in terms of clinical characteristics, pathologic features, and the most frequent chromosomal alterations, including loss of 1p, 10p, 10q, 13q, and 19q, and gain of 7p, 7q, 16p, 18q, 19p, 19q, 20p, and 22q. However, a genomic region located in 6q was more frequently gained in our series of familial as compared to sporadic gliomas (P=0.028). A germline TP53 mutation was observed in 1/9 cases, which suggests Li-Fraumeni syndrome. Interestingly, the Pro allele in the codon 72 of TP53 was observed in 5/9 tumors. Although familial and sporadic gliomas share very similar cytogenetic quantitative patterns, aCGH is a promising technique for the detection of small genomic differences of potential significance.

Entities:  

Mesh:

Year:  2007        PMID: 17656254     DOI: 10.1016/j.cancergencyto.2007.04.012

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  TP53 codon 72 polymorphism and glioma risk: A meta-analysis.

Authors:  Minghan Shi; Ruishan Huang; Chunying Pei; Xiuzhi Jia; Chuanlu Jiang; Huan Ren
Journal:  Oncol Lett       Date:  2011-12-12       Impact factor: 2.967

2.  The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis.

Authors:  Weijie Zhu; Lei Lu; Yi Li; Jie Yao; Bainan Xu
Journal:  Tumour Biol       Date:  2014-02-01

3.  EGFR gene amplification in monocentric and multicentric glioblastoma.

Authors:  Lucia Nichelli; Didier Dormont; Marc Sanson; Anna Luisa Di Stefano
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

4.  Genomic changes in progression of low-grade gliomas.

Authors:  Ahmed Idbaih; Rosana Carvalho Silva; Emmanuelle Crinière; Yannick Marie; Catherine Carpentier; Blandine Boisselier; Sophie Taillibert; Audrey Rousseau; Karima Mokhtari; François Ducray; Joelle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2008-07-11       Impact factor: 4.130

5.  Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222.

Authors:  V Enciso-Mora; F J Hosking; A L Di Stefano; D Zelenika; S Shete; P Broderick; A Idbaih; J-Y Delattre; K Hoang-Xuan; Y Marie; M Labussière; A Alentorn; P Ciccarino; M Rossetto; G Armstrong; Y Liu; K Gousias; J Schramm; C Lau; S J Hepworth; M Schoemaker; K Strauch; M Müller-Nurasyid; S Schreiber; A Franke; S Moebus; L Eisele; A Swerdlow; M Simon; M Bondy; M Lathrop; M Sanson; R S Houlston
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

6.  IDH mutations: genotype-phenotype correlation and prognostic impact.

Authors:  Xiao-Wei Wang; Pietro Ciccarino; Marta Rossetto; Blandine Boisselier; Yannick Marie; Virginie Desestret; Vincent Gleize; Karima Mokhtari; Marc Sanson; Marianne Labussière
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.